SELLAS Life Sciences Group, Inc. Operating Lease, Weighted Average Discount Rate, Percent
SELLAS Life Sciences Group, Inc. (SLS) had Operating Lease, Weighted Average Discount Rate, Percent of 13.00% as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-11
- 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 13.00%.
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 13.00%.
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 13.00%.
- 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 13.00%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2026-06-30 | 13.00% 10-Q · filed 2026-08-11 |
| 2026-03-31 | 13.00% 10-Q · filed 2026-05-12 |
| 2025-12-31 | 13.00% 10-K · filed 2026-03-19 |
| 2025-09-30 | 13.00% 10-Q · filed 2025-11-12 |
| 2025-06-30 | 13.00% 10-Q · filed 2025-08-12 |
| 2025-03-31 | 13.00% 10-Q · filed 2025-05-13 |
| 2024-12-31 | 13.00% 10-K · filed 2026-03-19 |
| 2024-09-30 | 13.00% 10-Q · filed 2024-11-13 |
| 2024-06-30 | 13.00% 10-Q · filed 2024-08-13 |
| 2024-03-31 | 13.00% 10-Q · filed 2024-05-14 |
| 2023-12-31 | 13.00% 10-K · filed 2025-03-20 |
| 2023-09-30 | 13.95% 10-Q · filed 2023-11-09 |
| 2023-06-30 | 13.95% 10-Q · filed 2023-08-10 |
| 2022-12-31 | 13.95% 10-K · filed 2023-03-16 |
| 2022-09-30 | 13.95% 10-Q · filed 2022-11-14 |
| 2022-06-30 | 13.95% 10-Q · filed 2022-08-11 |
| 2020-12-31 | 13.00% 10-K · filed 2021-03-23 |
| 2020-03-31 | 13.00% 10-Q · filed 2020-05-14 |
| 2019-12-31 | 13.00% 10-K · filed 2020-03-13 |
| 2019-09-30 | 13.00% 10-Q · filed 2019-11-14 |
| 2019-06-30 | 13.00% 10-Q · filed 2019-08-14 |
| 2019-03-31 | 13.00% 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |